OA11937A - HIV immunogenic compositions and methods. - Google Patents

HIV immunogenic compositions and methods. Download PDF

Info

Publication number: OA11937A
Authority: OA; OAPI
Prior art keywords: hiv; immunogenic composition; nucleic acid; antigen; iss
Prior art date: 1999-05-06

Application number

OA1200100291A

Other languages

English (en)

Inventor

Ronald B Moss

Original Assignee

Immune Response Corp Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-06

Filing date

2000-05-05

Publication date

2006-04-12

2000-05-05 Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc

2006-04-12 Publication of OA11937A publication Critical patent/OA11937A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 134
230000002163 immunogen Effects 0.000 title claims abstract description 93
238000000034 method Methods 0.000 title claims abstract description 45
241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 149
238000004519 manufacturing process Methods 0.000 claims abstract description 59
239000002671 adjuvant Substances 0.000 claims abstract description 53
108020004707 nucleic acids Proteins 0.000 claims abstract description 51
102000039446 nucleic acids Human genes 0.000 claims abstract description 51
150000007523 nucleic acids Chemical class 0.000 claims abstract description 51
102000001902 CC Chemokines Human genes 0.000 claims abstract description 48
108010040471 CC Chemokines Proteins 0.000 claims abstract description 48
241000124008 Mammalia Species 0.000 claims abstract description 38
208000030507 AIDS Diseases 0.000 claims abstract description 21
230000003308 immunostimulating effect Effects 0.000 claims abstract description 12
230000002708 enhancing effect Effects 0.000 claims abstract description 11
101710091045 Envelope protein Proteins 0.000 claims abstract description 9
101710188315 Protein X Proteins 0.000 claims abstract description 9
230000002401 inhibitory effect Effects 0.000 claims abstract description 6
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 51
210000004027 cell Anatomy 0.000 claims description 32
230000028993 immune response Effects 0.000 claims description 32
230000004044 response Effects 0.000 claims description 32
241000700605 Viruses Species 0.000 claims description 16
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 16
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 14
210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 13
241000288906 Primates Species 0.000 claims description 12
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 11
229940104302 cytosine Drugs 0.000 claims description 10
VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 claims description 10
230000003053 immunization Effects 0.000 claims description 9
229940046166 oligodeoxynucleotide Drugs 0.000 claims description 9
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 8
108010055166 Chemokine CCL5 Proteins 0.000 claims description 7
230000016784 immunoglobulin production Effects 0.000 claims description 7
241000283984 Rodentia Species 0.000 claims description 6
241000282412 Homo Species 0.000 claims description 4
241000186359 Mycobacterium Species 0.000 claims description 4
229940037003 alum Drugs 0.000 claims description 3
229940035032 monophosphoryl lipid a Drugs 0.000 claims description 2
102100021696 Syncytin-1 Human genes 0.000 claims 2
102000001327 Chemokine CCL5 Human genes 0.000 claims 1
102000036639 antigens Human genes 0.000 abstract description 103
108091007433 antigens Proteins 0.000 abstract description 103
239000000427 antigen Substances 0.000 abstract description 102
101710147327 Calcineurin B homologous protein 1 Proteins 0.000 abstract description 38
101710205625 Capsid protein p24 Proteins 0.000 abstract description 38
101710177166 Phosphoprotein Proteins 0.000 abstract description 38
101710149279 Small delta antigen Proteins 0.000 abstract description 38
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 abstract description 38
102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 abstract 1
108010074328 Interferon-gamma Proteins 0.000 description 32
102100037850 Interferon gamma Human genes 0.000 description 29
210000001744 T-lymphocyte Anatomy 0.000 description 27
208000031886 HIV Infections Diseases 0.000 description 19
208000037357 HIV infectious disease Diseases 0.000 description 19
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 19
102000004127 Cytokines Human genes 0.000 description 13
108090000695 Cytokines Proteins 0.000 description 13
238000011282 treatment Methods 0.000 description 13
230000000694 effects Effects 0.000 description 12
229960005486 vaccine Drugs 0.000 description 11
208000015181 infectious disease Diseases 0.000 description 9
230000004048 modification Effects 0.000 description 9
238000012986 modification Methods 0.000 description 9
230000003389 potentiating effect Effects 0.000 description 9
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
102100032367 C-C motif chemokine 5 Human genes 0.000 description 7
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 7
239000002253 acid Substances 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 6
206010061818 Disease progression Diseases 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
230000005750 disease progression Effects 0.000 description 6
238000002649 immunization Methods 0.000 description 6
210000001165 lymph node Anatomy 0.000 description 6
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
102000019034 Chemokines Human genes 0.000 description 5
108010012236 Chemokines Proteins 0.000 description 5
238000003556 assay Methods 0.000 description 5
230000023385 chemokine (C-C motif) ligand 5 production Effects 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
238000011694 lewis rat Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
208000010648 susceptibility to HIV infection Diseases 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
239000012980 RPMI-1640 medium Substances 0.000 description 4
241000700159 Rattus Species 0.000 description 4
238000007792 addition Methods 0.000 description 4
230000000840 anti-viral effect Effects 0.000 description 4
230000005875 antibody response Effects 0.000 description 4
229960002685 biotin Drugs 0.000 description 4
235000020958 biotin Nutrition 0.000 description 4
239000011616 biotin Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000001472 cytotoxic effect Effects 0.000 description 4
210000003754 fetus Anatomy 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 3
101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 3
238000012286 ELISA Assay Methods 0.000 description 3
108010027044 HIV Core Protein p24 Proteins 0.000 description 3
102000008070 Interferon-gamma Human genes 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
229930182816 L-glutamine Natural products 0.000 description 3
241001504519 Papio ursinus Species 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
101800001690 Transmembrane protein gp41 Proteins 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
230000001464 adherent effect Effects 0.000 description 3
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
230000002596 correlated effect Effects 0.000 description 3
230000001461 cytolytic effect Effects 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
230000036541 health Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
229960000380 propiolactone Drugs 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
235000019333 sodium laurylsulphate Nutrition 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
229940021747 therapeutic vaccine Drugs 0.000 description 3
241000283707 Capra Species 0.000 description 2
101710132601 Capsid protein Proteins 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
238000011510 Elispot assay Methods 0.000 description 2
229940033330 HIV vaccine Drugs 0.000 description 2
101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
102000004388 Interleukin-4 Human genes 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
-1 aluminum salts Chemical class 0.000 description 2
230000036436 anti-hiv Effects 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
239000012636 effector Substances 0.000 description 2
229940044627 gamma-interferon Drugs 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000028996 humoral immune response Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
238000004969 ion scattering spectroscopy Methods 0.000 description 2
210000002751 lymph Anatomy 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
KDWFDOFTPHDNJL-TUBOTVQJSA-N odn-2006 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 KDWFDOFTPHDNJL-TUBOTVQJSA-N 0.000 description 2
238000004091 panning Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
238000000053 physical method Methods 0.000 description 2
229920002627 poly(phosphazenes) Polymers 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
238000009589 serological test Methods 0.000 description 2
241000894007 species Species 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
206010001513 AIDS related complex Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
102000004274 CCR5 Receptors Human genes 0.000 description 1
108010017088 CCR5 Receptors Proteins 0.000 description 1
241001428800 Cell fusing agent virus Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
206010071602 Genetic polymorphism Diseases 0.000 description 1
229940033332 HIV-1 vaccine Drugs 0.000 description 1
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
241000282553 Macaca Species 0.000 description 1
102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
241001644525 Nastus productus Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
241000282520 Papio Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010047620 Phytohemagglutinins Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
101001043830 Rattus norvegicus Interleukin-2 Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
101710182223 Toxin B Proteins 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
238000010171 animal model Methods 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001889 chemoattractive effect Effects 0.000 description 1
230000014564 chemokine production Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
101150008740 cpg-1 gene Proteins 0.000 description 1
101150071119 cpg-2 gene Proteins 0.000 description 1
101150014604 cpg-3 gene Proteins 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
108700004026 gag Genes Proteins 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000036512 infertility Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
230000035772 mutation Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
230000001885 phytohemagglutinin Effects 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
150000003071 polychlorinated biphenyls Chemical group 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
229940021993 prophylactic vaccine Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000012552 review Methods 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000002522 swelling effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000010257 thawing Methods 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000001262 western blot Methods 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

OA1200100291A 1999-05-06 2000-05-05 HIV immunogenic compositions and methods. OA11937A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13276299P	1999-05-06	1999-05-06
US15066799P	1999-08-25	1999-08-25

Publications (1)

Publication Number	Publication Date
OA11937A true OA11937A (en)	2006-04-12

Family

ID=26830710

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100291A OA11937A (en)	1999-05-06	2000-05-05	HIV immunogenic compositions and methods.

Country Status (8)

Country	Link
EP (1)	EP1176978A2 (pt)
AP (1)	AP1891A (pt)
AU (1)	AU4992900A (pt)
BR (1)	BR0010323A (pt)
CA (1)	CA2372960C (pt)
CR (1)	CR6491A (pt)
OA (1)	OA11937A (pt)
WO (1)	WO2000067787A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
SI1077722T1 (sl)	1998-05-22	2007-02-28	Ottawa Health Research Inst	Metode in produkti za induciranje sluznicne imunosti
AU2221600A (en)	1998-12-31	2000-07-31	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
AU2487300A (en)	1998-12-31	2000-07-31	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
ES2572834T3 (es)	1999-02-17	2016-06-02	Csl Limited	Complejos inmunogénicos y métodos relacionados con los mismos
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
AU5821000A (en) *	1999-06-29	2001-01-31	Smithkline Beecham Biologicals (Sa)	Vaccine
AU2001227889A1 (en)	2000-01-14	2001-07-24	The United States of America, represented by The Secretary, Department of Health & Human Services	Oligodeoxynucleotide and its use to induce an immune response
KR100881923B1 (ko)	2000-12-27	2009-02-04	다이나박스 테크놀로지 코퍼레이션	면역자극 폴리뉴클레오티드 및 그것의 사용 방법
SG152045A1 (en) *	2001-01-26	2009-05-29	Immune Response Corp Inc	Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment
EP2423335B1 (en)	2001-06-21	2014-05-14	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same
EP1411770A4 (en)	2001-07-05	2006-05-10	Chiron Corp	POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
WO2003020884A2 (en)	2001-08-14	2003-03-13	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Method for rapid generation of mature dendritic cells
ATE411054T1 (de)	2001-08-17	2008-10-15	Coley Pharm Gmbh	Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
US20030170614A1 (en)	2001-08-31	2003-09-11	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
AR045702A1 (es)	2001-10-03	2005-11-09	Chiron Corp	Composiciones de adyuvantes.
WO2003054161A2 (en)	2001-12-20	2003-07-03	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
CA2388049A1 (en)	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
WO2004005476A2 (en) *	2002-07-03	2004-01-15	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en)	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en)	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
CN1753687A (zh)	2002-10-29	2006-03-29	科勒制药集团股份有限公司	Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
CA2502015A1 (en)	2002-12-11	2004-06-24	Coley Pharmaceutical Group, Inc.	5' cpg nucleic acids and methods of use
US8158768B2 (en)	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
JP5102959B2 (ja)	2002-12-23	2012-12-19	ダイナバックステクノロジーズコーポレイション	免疫刺激配列オリゴヌクレオチド及びその使用方法
MXPA06001996A (es) *	2003-08-28	2006-06-20	Immune Response Corp Inc	Composiciones de hiv inmunogeneticas y metodos relacionados.
MY159370A (en)	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
PT2078080E (pt)	2006-09-27	2015-09-18	Coley Pharm Gmbh	Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
WO2010051820A1 (en) *	2008-11-10	2010-05-14	Aarhus Universitet	Multiplexed cytokine vaccination
MX350258B (es)	2011-07-06	2017-08-31	Novartis Ag	Emulsiones cationicas de aceite en agua.
JP6059220B2 (ja)	2011-07-06	2017-01-18	ノバルティスアーゲー	核酸を含む水中油型エマルジョン

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1005368T3 (da) *	1997-03-10	2010-01-04	Ottawa Hospital Res Inst	Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
EP1003850B1 (en) *	1997-06-06	2009-05-27	The Regents of the University of California	Inhibitors of dna immunostimulatory sequence activity

2000
- 2000-05-05 WO PCT/US2000/012495 patent/WO2000067787A2/en not_active Ceased
- 2000-05-05 CA CA002372960A patent/CA2372960C/en not_active Expired - Fee Related
- 2000-05-05 BR BR0010323-3A patent/BR0010323A/pt not_active IP Right Cessation
- 2000-05-05 AU AU49929/00A patent/AU4992900A/en not_active Abandoned
- 2000-05-05 EP EP00932163A patent/EP1176978A2/en not_active Withdrawn
- 2000-05-05 AP APAP/P/2001/002300A patent/AP1891A/en active
- 2000-05-05 OA OA1200100291A patent/OA11937A/en unknown
2001
- 2001-10-25 CR CR6491A patent/CR6491A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
BR0010323A (pt)	2002-01-08
AP1891A (en)	2008-09-23
WO2000067787A2 (en)	2000-11-16
AU4992900A (en)	2000-11-21
EP1176978A2 (en)	2002-02-06
CA2372960A1 (en)	2000-11-16
AP2001002300A0 (en)	2001-12-31
CA2372960C (en)	2006-03-28
CR6491A (es)	2005-05-31
WO2000067787A3 (en)	2001-04-26

Publication	Publication Date	Title
US6737066B1 (en)	2004-05-18	HIV immunogenic compositions and methods
CA2372960C (en)	2006-03-28	Hiv immunogenic compositions and methods
NO314588B1 (no)	2003-04-14	HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
Fast et al.	1993	Human trials of experimental AIDS vaccines
EP2552480A1 (en)	2013-02-06	Hiv vaccine
US20050196411A1 (en)	2005-09-08	Immunogenic HIV compositions and related methods
Valentine et al.	1996	A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with⩾ 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)
US20030044428A1 (en)	2003-03-06	Method for treating an HIV-infected individual by combining immunization with structured interruption of anti-retroviral treatment
AU2005222909B2 (en)	2010-03-11	Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide
Lore et al.	2009	Novel adjuvants for B cell immune responses
Tramont et al.	2003	Progress in the development of an HIV vaccine
Robinson et al.	2003	Parasitic infection and the polarized Th2 immune response can alter a vaccine-induced immune response
Silvera et al.	2004	Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques
ZA200108559B (en)	2002-06-06	HIV immunogenic compositions and methods.
Benferhat et al.	2009	The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope
MXPA01010784A (en)	2002-06-05	Hiv immunogenic compositions and methods
Calarota et al.	2001	Cellular HIV-1 immune responses in natural infection and after genetic immunization
KR20070019635A (ko)	2007-02-15	면역원성 ｈｉｖ 조성물 및 이와 관련된 방법
WO1994002171A1 (en)	1994-02-03	Prophylactic and therapeutic control of retroviral infections
WO1994002171A9 (en)	1994-04-28	Prophylactic and therapeutic control of retroviral infections
HK1114789A (en)	2008-11-14	Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
Rivera	2006	Immunogenic properties of synthetic peptide mixture derived from the hypervariable regions of HIV-1 envelope glycoprotein gp120